Skip to main
  1. Stocks
  2. Kymera Therapeutics
  3. Forecast
KYMR

Kymera Therapeutics (KYMR) Stock Forecast & Price Target

Kymera Therapeutics (KYMR) Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 48%
Buy 43%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Kymera Therapeutics is attractive because its targeted protein degradation platform is producing unusually strong early clinical validation across multiple programs, with KT-621 showing biologics-like efficacy in atopic dermatitis and KT-579 delivering >90% IRF5 degradation plus robust downstream biomarker inhibition. The company’s differentiated strategy is supported by clean safety signals, strong mechanistic rationale against historically hard-to-drug targets like STAT6 and IRF5, and a meaningful market opportunity in large autoimmune and immunology indications where oral alternatives could expand treatment uptake. The presence of a partnered IRAK4 program, continued pipeline expansion, and cash runway into 2029 further strengthen the fundamental case by reducing execution risk while preserving multiple near- and medium-term catalysts.

Bears say

Kymera Therapeutics is viewed negatively because its lead programs face substantial clinical and competitive risk, especially if KT-621 fails to show compelling efficacy versus key atopic dermatitis and asthma rivals in Ph2 BROADEN. The company also faces uncertainty from a novel degrader modality, where longer dosing could reveal prohibitive toxicity, compensatory signaling, or other safety issues not yet evident in early studies. Fundamentally, the outlook is pressured by the possibility that promising preclinical and early clinical signals will not translate into durable physician and patient enthusiasm, while regulatory, competitive, and pricing risks remain elevated, including pricing reform in the orphan space.

Kymera Therapeutics (KYMR) has been analyzed by 23 analysts, with a consensus rating of Buy. 48% of analysts recommend a Strong Buy, 43% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kymera Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Kymera Therapeutics (KYMR) Analyst Forecast & Price Prediction

Get the latest Kymera Therapeutics (KYMR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Kymera Therapeutics (KYMR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kymera Therapeutics (KYMR) Forecast

Analysts have given Kymera Therapeutics (KYMR) a Buy based on their latest research and market trends.

According to 23 analysts, Kymera Therapeutics (KYMR) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $136.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $136.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kymera Therapeutics (KYMR)


Kymera Therapeutics (KYMR) Analyst Forecast & Price Prediction

Get the latest Kymera Therapeutics (KYMR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Kymera Therapeutics (KYMR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover KYMR stock data and trends